The anticonvulsant effect of 17AAG in an acute seizure model. (A) Representative Western blot of GLT-1 in the hippocampus of mice 24 h after receiving i.p. injection of 17AAG three times weekly for 1 wk at the indicated dose. Bar graph shows relative fold change of GLT-1 (n = 4 mice per group; *, P < 0.05; **, P < 0.01; ***, P < 0.001, one-way ANOVA, post hoc Dunnett's test). Data are representative of two independent experiments. (B) Western blot of GLT-1 in the hippocampus of 17AAG-injected mice at the indicated time point after 17AAG injection (25 mg/kg). Bar graph shows relative fold change of GLT-1 (n = 3 for each time point). Data are representative of two independent experiments. (C) Experimental protocol for drug testing in an acute seizure model. Wild-type mice implanted with a hippocampal electrode and cannula were injected once with 17AAG 24 h before testing. The first EEG recording period (1 h) was used to assess the baseline of EEG activity. The vEEG was then recorded continuously after intrahippocampal KA injection (10 ng KA in 0.5 µl of PBS) for 3 h. All mice were recovered from KA-induced acute seizures within 3 h. (D–G) The EEG data were analyzed, and the total number of seizures, the duration from the first to the last seizure event (Time in seizures), the onset time after KA injection, and mean duration of each seizure are presented (n = 8 mice per group; *, P < 0.05; **, P < 0.01, one-way ANOVA, post hoc Dunnett's test). Data are combined from four independent experiments.